All In Biotech

Drug Trial Radar · NCT07946068

Aleniglipron Renal Impairment Study

A Phase 1, Single-Dose, Open-Label Study to Evaluate the Effect of Renal Impairment on Aleniglipron Pharmacokinetics

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of severe RI on IHD on the PK of aleniglipron to establish scientifically guided dosing recommendations in these special patient populations.

Conditions

  • Renal Impairment
  • Severe Renal Impairment

Interventions

  • AleniglipronDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma PK parameters for aleniglipron including, but not limited to AUC0-tTime frame: Baseline to Day 3
  2. Plasma PK parameters for aleniglipron including, but not limited to AUC0-infTime frame: Baseline to Day 3
  3. Plasma PK parameters for aleniglipron including, but not limited to CmaxTime frame: Baseline to Day 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Orlando, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.